Wednesday, 18 December 2019

Parkinsons Congress 2020

About Conference


Conference Series LLC LTD proudly presents 6th World Congress on Parkinson’s & Huntington’s disease. We invite participants around the world to Rome, Italy for Parkinson's Congress 2020 held during September 20-21, 2020.
Parkinson's Congress deals with Neurological Syndromes caused due to leakage of electric impulse in neurons which leads to loss of communication. This kind of medical conditions are getting frequent in humans at present situations. It has been observed there are number of diseases associated with Neurological disorders for examples Parkinson’s diseasesHuntington’sAlzheimer’s diseasebrain tumours, Multiple SclerosisSpinal Muscular Atrophy, Brain StrokeEpilepsyAmyotrophic Lateral Sclerosis.
According to current survey Neurological disorders occupy first place in Europe Brain disorders are like Brain Tumour, Cerebral palsychiari malformationCraniofacial abnormalitiesCraniosynostosisDevelopmental disordersEncephalopathyEpilepsy are recognized by World Health Organization in Europe. It is been identified 1.2 million people in Europe are suffering with Parkinson’s approximately 260000 people in Germany, 200000 people in Italy, 150000 people in Spain, 120000 people in UK, 117000 people in France are suffering from Parkinson's disease.
World Health Organization (WHO) and World Federation of Neurology (WFN) were collaborated after find the rate of Neurological disorders worldwide. An international Survey of Country Resources for Neurological disorders effects 109 countries and covering over 90% of the world’s population. This survey helps to collect valuable information regarding aspects of neurological care all around the world.  
 At National Institute of Health funding package is of $34 billion for the economic year 2017 to improve life of patients who are suffering from Parkinson’s disease and to raise the awareness on Neurological disorders around the World. PRP (Parkinson's Research Program) fund received amount of $16 million annually to research in neuromuscular disorders such as Alzheimer’s, Parkinson’s disease and Huntington’s disease.

Conference Highlights

 
Session onParkinson Disease
Parkinson’s disease (PD) is a chronic and progressive disease of nervous system that possess symptoms which continue and become worse over time. It is the second commonest neurodegenerative disease after Alzheimer's disease, and in the UK, has a lifetime prevalence of between 0.1 and 0.3% of the population. The basic reason behind this condition is malfunction and death of vital nerve cells in brain. In normal conditions nerve cells present in the brain produces a neurotransmitter called dopamine that is responsible for signalling movement, emotions and co-ordination but in the case of diseased individual dopamine production slows down, hence the individual become unable to control the movement normally. There is no cure but treatment involves medication and surgery. Slowness of voluntary movements, reduced facial appearance, repetitious tongue, and diminished eye flashing, A shuffling gait with deprived arm swing and curved posture, Shaky stability; difficulty rising from a sitting position, Swallowing problems in later stages.
13th Annual Conference on Dementia and Alzheimer’s Disease, December 13-15, 2018 Abu Dhabi, UAE; World Brain Congress, December 5-7, 2018 Dubai, UAE; 13th International Conference on Neurology and Brain Disorders, November 15-16, 2018 Osaka, Japan; World Neuron Congress , November 19-21, 2018 Bucharest, Romania; 5th World Parkinson Congress, June 4-7 2019; Comprehensive Review of Movement Disorders for the Clinical PractitionerInternational Parkinson & Movement Disorder Society,  Northwest Parkinson’s FoundationAmerican Neurological AssociationWorld Parkinson CoalitionAmerican Parkinson’s Disease Association
Associations:
Parkinson's disease is a neurodegenerative disorder and the cause of it remained a mystery to the scientific community. Researchers say by exposing to harmful chemicals and Pesticides mutations occurs in the genes and results in neurological disorders. With age, the condition of disease increases exponentially and men are in higher proportion to prone compared to women. On an average 10million individuals are found to be suffering from Parkinson’s disease, from where only four present of people with Parkinson’s disease are diagnosed before the age of 50. An estimated of 40% to 60% of Parkinson disease patients suffering from depression. United States stands in the fourth position in considering the death of people due to Parkinson’s disease.
 
11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  World Depression Congress, March 18-20, 2019 at Dubai, UAE, 11th World Congress on Alzheimer's Disease and Dementia,  March 20-21, 2019 at Sydney, Australia15th International Conference on Dementia and Alzheimer’s Disease, March 25-26, 2019 at Osaka, Japan, 31st World Neuroscience Congress Osaka, Japan during March 25-26, 2019, International Conference & Exhibition on Addictive Disorders & Addiction Therapy, March 25-26, 2019 in Yokohama, Japan, 26th World Congress on Neurology and Neuro disorders April 22-23, 2019 at Tokyo, Japan, 5th International Conference on Spine and Spinal Disorders, April 25th & 26th, 2019 at Rome, Italy, 5th Global Experts Meeting on Parkinson’s, Huntington’s Movement Disorders, May 08 – 09,2019 Tokyo, Japan, 5th International Conference on Neurological Disorders and Stroke may 20-21,2019 at Osaka, Japan,  28th World Congress on Neurology & Neuroscience, Zurich, Switzerland, May 23-24, 2019, 5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neuro genetics Conference, November 19-20, 2019 in Istanbul, Turkey
Associations:
Neurons are the specialized cells that are responsible for communication, when they cannot produce signals communication between nervous system breaks and results in neuromuscular disorders. Most of these disorders are thought be inheritable and treatment is given to improve the life of patient and no cure is available to completely eradicate the condition.
Associations:
Huntington’s disease is inherited from Parents and often symptoms will be more like Parkinson’s disease which include problem with mood, mental abilities, Swallowing, Speaking, Sleep Disturbances followed by loss of co-ordination and unsteady gait. A gene called HTT(Huntingtin) which is responsible for coding protein Huntingtin, if any mutation to that gene it will cause disturbances in the brain and results in death of brain cell and leads to Huntington’s disease. Abnormalities with the mutant huntingtin include Cardiac Failure, Weight Loss, Osteoporosis, reduced glucose level. This condition is normally observed in the individuals under the age of fifties.
13th Annual Conference on Dementia and Alzheimer’s Disease, December 13-15, 2018 Abu Dhabi, UAE; World Brain Congress, December 5-7, 2018 Dubai, UAE; 13th International Conference on Neurology and Brain Disorders, November 15-16, 2018 Osaka, Japan; World Neuron Congress , November 19-21, 2018 Bucharest, Romania; 5th World Parkinson Congress, June 4-7 2019; Comprehensive Review of Movement Disorders for the Clinical PractitionerInternational Parkinson & Movement Disorder Society,  Northwest Parkinson’s FoundationAmerican Neurological AssociationWorld Parkinson CoalitionAmerican Parkinson’s Disease Association
Associations:
Symptoms and progression of disease will not be similar among the suffering individuals but people with Parkinson’s are at higher rate of developing related risks. Developing these conditions is not a certainty, only a possibility. Knowing the conditions can help a person with Parkinson’s disease or associated symptoms and helps to take preventative measures for a better life. Parkinson’s disease has a chance of creating mental ailment which can be mild or serious. It includes cognition (early stage symptoms), mood, and behaviour which are considered as major impairment when compared to normal population. The common mood alterations seen in the patients are despair, eagerness, indifference.
11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  World Depression Congress, March 18-20, 2019 at Dubai, UAE, 11th World Congress on Alzheimer's Disease and Dementia,  March 20-21, 2019 at Sydney, Australia15th International Conference on Dementia and Alzheimer’s Disease, March 25-26, 2019 at Osaka, Japan, 31st World Neuroscience Congress Osaka, Japan during March 25-26, 2019, International Conference & Exhibition on Addictive Disorders & Addiction Therapy, March 25-26, 2019 in Yokohama, Japan, 26th World Congress on Neurology and Neurodisorders April 22-23, 2019 at Tokyo, Japan, 5th International Conference on Spine and Spinal Disorders, April 25th & 26th, 2019 at Rome, Italy, 5th Global Experts Meeting on Parkinson’s, Huntington’s Movement Disorders, May 08 – 09,2019 Tokyo, Japan, 5th International Conference on Neurological Disorders and Stroke may 20-21,2019 at Osaka, Japan,  28th World Congress on Neurology & Neuroscience, Zurich, Switzerland, May 23-24, 2019, 5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neuro genetics Conference, November 19-20, 2019 in Istanbul, Turkey
Associations:
Parkinson’s disease is originated because of the gradual loss of cells in the substantia nigra of the brain. Dopamine is a neurotransmitter that transmits signals between two regions of the brain to coordinate activities like movement of limbs. If there is deficiency in dopamine production results in loss of co-ordination and end up with symptoms of Parkinson’s disease. As the disease progresses, nervous system and brain degenerates causing a higher movement disorder.
Associations:
Early stage identification of Parkinson’s disease is difficult but includes some imaging studies. MRI (magnetic resonance imaging) and CT (computer tomogram) are used by many physicians to find out other relating Parkinson’s diseases such as encephalitis, Tumours, Hydrocephalus. Level of dopamine release and activity of brain can easily detect using PET and SPECT examining.
13th Annual Conference on Dementia and Alzheimer’s Disease, December 13-15, 2018 Abu Dhabi, UAE; World Brain Congress, December 5-7, 2018 Dubai, UAE; 13th International Conference on Neurology and Brain Disorders, November 15-16, 2018 Osaka, Japan; World Neuron Congress , November 19-21, 2018 Bucharest, Romania; 5th World Parkinson Congress, June 4-7 2019; Comprehensive Review of Movement Disorders for the Clinical PractitionerInternational Parkinson & Movement Disorder Society,  Northwest Parkinson’s FoundationAmerican Neurological AssociationWorld Parkinson CoalitionAmerican Parkinson’s Disease Association
Associations:
Parkinson's disease is usually accompanied by additional problems, which may be cured and they are thinking difficulties, swallowing problems, depression and emotional changes, sleep difficulties, constipation, blood pressure changes, fatigue, pain.
11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  World Depression Congress, March 18-20, 2019 at Dubai, UAE, 11th World Congress on Alzheimer's Disease and Dementia,  March 20-21, 2019 at Sydney, Australia15th International Conference on Dementia and Alzheimer's Disease, March 25-26, 2019 at Osaka, Japan, 31st World Neuroscience Congress Osaka, Japan during March 25-26, 2019, International Conference & Exhibition on Addictive Disorders & Addiction Therapy, March 25-26, 2019 in Yokohama, Japan, 26th World Congress on Neurology and Neurodisorders April 22-23, 2019 at Tokyo, Japan, 5th International Conference on Spine and Spinal Disorders, April 25th & 26th, 2019 at Rome, Italy, 5th Global Experts Meeting on Parkinson’s, Huntington’s Movement Disorders, May 08 – 09,2019 Tokyo, Japan, 5th International Conference on Neurological Disorders and Stroke may 20-21,2019 at Osaka, Japan,  28th World Congress on Neurology & Neuroscience, Zurich, Switzerland, May 23-24, 2019, 5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neuro genetics Conference, November 19-20, 2019 in Istanbul, Turkey
Associations:
The known cause of Parkinson’s disease is reduced level of dopamine production by neurons in the brain but surprisingly the main cause was malfunctioning of cell organelles like mitochondria leads to increased oxidative stress which in turn results in cell death and finally ends with Parkinson’s disease with motor and non-motor symptoms. The reason may be both genetic and environment factors.
Associations:
No cure has been identified to Parkinson’s disease, but use of drugs can slow down the progression. Normally prescribed by physicians include change of life style, regular aerobic exercise and prescribed therapeutic supplement. It is noted that people will have beneficial effect who are taking co-enzyme Q10 during their initial stage of disease. It is unclear how genetically changes cause Parkinson disease or influence the risk of developing the disorder. Some gene mutations(alterations) such as LRRK 2, PARK 7, PINK 1, PRKN disturb the cell mechanism that breaks down undesired proteins in neurons which are responsible for dopamine production. Hence, under graded proteins accumulate, resulting in death of vital nerve cells and subsequently lowers the level of dopamine production. In most cases of Parkinson disease, protein deposits called Lewy bodies. It is unclear whether Lewy bodies play a key role in killing nerve cells or just part of the cells which are responsible to the disease. Yoga, massage, acupuncture, meditation, music or art therapy, alexander technique is also regarding as best methods to control neurological disorders particularly Parkinson’s disease, Alzheimer’s and neuropsychiatric. Tetrabenazine, neuroleptics, mirtazapine can be taken to for treating chorea.
11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  World Depression Congress, March 18-20, 2019 at Dubai, UAE, 11th World Congress on Alzheimer's Disease and Dementia,  March 20-21, 2019 at Sydney, Australia15th International Conference on Dementia and Alzheimer’s Disease, March 25-26, 2019 at Osaka, Japan, 31st World Neuroscience Congress Osaka, Japan during March 25-26, 2019, International Conference & Exhibition on Addictive Disorders & Addiction Therapy, March 25-26, 2019 in Yokohama, Japan, 26th World Congress on Neurology and Neurodisorders April 22-23, 2019 at Tokyo, Japan, 5th International Conference on Spine and Spinal Disorders, April 25th & 26th, 2019 at Rome, Italy, 5th Global Experts Meeting on Parkinson’s, Huntington’s Movement Disorders, May 08 – 09,2019 Tokyo, Japan, 5th International Conference on Neurological Disorders and Stroke may 20-21,2019 at Osaka, Japan,  28th World Congress on Neurology & Neuroscience, Zurich, Switzerland, May 23-24, 2019, 5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neurogenesis Conference, November 19-20, 2019 in Istanbul, Turkey
Associations:
Since the symptoms and progression of disease are not similar among individuals early stage detection can help to reduce the worseness. Treatment and complete abolition is not known to research groups but maintaining the instructions and following the medication prescribed by physician can better the life. Individual should get practised to maintain the stress levels and depression by daily communicating with close relatives, friends. Patients can improve the life by following guidelines given by counsellor.
13th Annual Conference on Dementia and Alzheimer’s Disease, December 13-15, 2018 Abu Dhabi, UAE; World Brain Congress, December 5-7, 2018 Dubai, UAE; 13th International Conference on Neurology and Brain Disorders, November 15-16, 2018 Osaka, Japan; World Neuron Congress , November 19-21, 2018 Bucharest, Romania; 5th World Parkinson Congress, June 4-7 2019; Comprehensive Review of Movement Disorders for the Clinical PractitionerInternational Parkinson & Movement Disorder Society,  Northwest Parkinson’s FoundationAmerican Neurological AssociationWorld Parkinson CoalitionAmerican Parkinson’s Disease Association
Associations:
 
Session on: Neurosurgery
Presently Deep brain stimulation is widely recommended for improving people suffering with Parkinson’s disease one is deep brain stimulation (DBS) and is performed by inserting a tube in the small intestine and is used to treat a variety of deactivating neurological symptoms most commonly the draining symptoms of Parkinson’s disease (PD), such as tremor, rigidity, stiffness, slowed movement, and walking problems. There will be no effect with using DBS to healthy brain tissue by terminating nerve cells. Instead the procedure blocks electrical signals from targeted areas in the brain.
Associations:
Free radicles have both beneficial and baleful effect to human body. These are produced with in the body by metabolism and enters body through external sources such as pollution, radiation, therapeutics etc; Oxidative stress is known to cause many neurological diseases such as Alzheimer’s, Parkinson’s disease, Amyotrophic lateral sclerosis(ALS). With oldness, there is a typical failure of the dopamine producing neurons. Out of surprise 2% of the 1 million people with the disease are thought to be below the age of fifty. In some of the rare situations symptoms are seen in children and teens and it is known as juvenile Parkinsonism.
Associations:
Session onNovel Therapeutics
The commonly used drug to treat Parkinson’s disease is Levodopa which has higher frequency to develop motor Fluctuations and results in L-dopa-induced dyskinesia (LID). Since the Characteristic key cause of Parkinson’s disease is reduced production level dopamine by neurons, research studies developed a molecule called LXR (Liver X Receptor) where it has got potential to reduce the loss of dopaminergic neurons. Researchers propose novel ideas to treat Parkinson’s disease to reduce the risk of causing side effects, frequency of dyskinesia, to treat cognitive disorders such as anxiety and depression.
11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  World Depression Congress, March 18-20, 2019 at Dubai, UAE, 11th World Congress on Alzheimer's Disease and Dementia,  March 20-21, 2019 at Sydney, Australia15th International Conference on Dementia and Alzheimer’s Disease, March 25-26, 2019 at Osaka, Japan, 31st World Neuroscience Congress Osaka, Japan during March 25-26, 2019, International Conference & Exhibition on Addictive Disorders & Addiction Therapy, March 25-26, 2019 in Yokohama, Japan, 26th World Congress on Neurology and Neurodisorders April 22-23, 2019 at Tokyo, Japan, 5th International Conference on Spine and Spinal Disorders, April 25th & 26th, 2019 at Rome, Italy, 5th Global Experts Meeting on Parkinson’s, Huntington’s Movement Disorders, May 08 – 09,2019 Tokyo, Japan, 5th International Conference on Neurological Disorders and Stroke may 20-21,2019 at Osaka, Japan,  28th World Congress on Neurology & Neuroscience, Zurich, Switzerland, May 23-24, 2019, 5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neuro genetics Conference, November 19-20, 2019 in Istanbul, Turkey
Associations:
To develop a promising drug or treatment for Parkinson’s disease observational study is being conducted by scientist in laboratory to provide patients with better life. Clinical trials are performed to slowdown the progression and reduce the symptoms.
11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  World Depression Congress, March 18-20, 2019 at Dubai, UAE, 11th World Congress on Alzheimer's Disease and Dementia,  March 20-21, 2019 at Sydney, Australia15th International Conference on Dementia and Alzheimer’s Disease, March 25-26, 2019 at Osaka, Japan, 31st World Neuroscience Congress Osaka, Japan during March 25-26, 2019, International Conference & Exhibition on Addictive Disorders & Addiction Therapy, March 25-26, 2019 in Yokohama, Japan, 26th World Congress on Neurology and Neurodisorders April 22-23, 2019 at Tokyo, Japan, 5th International Conference on Spine and Spinal Disorders, April 25th & 26th, 2019 at Rome, Italy, 5th Global Experts Meeting on Parkinson’s, Huntington’s Movement Disorders, May 08 – 09,2019 Tokyo, Japan, 5th International Conference on Neurological Disorders and Stroke may 20-21,2019 at Osaka, Japan,  28th World Congress on Neurology & Neuroscience, Zurich, Switzerland, May 23-24, 2019, 5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neurogenetics Conference, November 19-20, 2019 in Istanbul, Turkey
Associations:
 
Parkinson's disease is frequently associated with Psychological disorders like psychotic disorders, depression, psychotic disorders, and dementia after examination of psychological disorders in Parkinson’s disease one-third of Parkinson's patients experience visual hallucinationsMood disorder and depressive symptoms are common in Parkinson's patients.
It is clear that Parkinson's disease is associated with psychological disorders which can be treated with Chemotherapy (drugs) but according to clinical trials drugs for psychological disorders can give side effect on patient so it is vital to know about the theraptic drug used for Parkinson's psychological disorders. Dose reduction of certain anitpakinsoian drugs sometimes improve psychotic disorders, Clozapine is effective and does not worse Parkinson’s symptoms
 

Special Issues

 
  •  Journal of Neurological Disorders
  • Journal of Neurology & Neurophysiology
  • Journal of Alzheimers Disease & Parkinsonism
 All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.
Abstracts will be provided with Digital Object Identifier by Cross Ref

See more at: https://recycling.environmentalconferences.org/